Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease. It’s main feature is the nigrostriatal neuronal cell loss resulting in striatal dopamine (DA) deficiency. L-dopa + peripheral amino acid decarboxylase inhibitor (DDI: Sinemet or Madopar) is still the most effective agent for the symptomatic treatment of PD, but the dopa therapy is far from perfect. For advanced cases especially for patients with wearing off of the drug effect, fluctuation of response and “on-off, ” the conventional preparation such as Sinemet or Madopar due to their short T1/2 is no longer suitable for clinical use. Thus controlled release preparation e.g. Sinemet CR or Madopar HBS is preferable.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Xu, D.L. (1995). Medical Treatment of Parkinson’s Disease. In: Tang, L.C., Tang, S.J. (eds) Neurochemistry in Clinical Application. Advances in Experimental Medicine and Biology, vol 363. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1857-0_4
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1857-0_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5754-4
Online ISBN: 978-1-4615-1857-0
eBook Packages: Springer Book Archive